Benicar
(Olmesartan medoxomil)ApprovedSmall molecule
Olmesartan medoxomil is used to treat high blood pressure and help reduce the risk of heart disease and stroke.[2] Benicar is currently approved and in use across 6 indications[4].[1]
Benicar is one of 209 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.
6
Indications
54
Total Trials
0
Active Trials
208
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
190 competitors in Obesity
#DrugCompanyPhaseTrials
1Benicar
CCosette Pharmaceuticals, Inc.
Approved
Maridebart Cafraglutide
AmgenPhase 3
NNC0487-0111
Novo NordiskPhase 3
Gemtesa
Sumitomo Pharma America, Inc.Phase 3
Zenagamtide
Novo NordiskPhase 3
Berobenatide
PfizerPhase 3
Ribupatide
KKailera
Phase 3
Elecoglipron
AstraZenecaPhase 3
PF-08653944
PfizerPhase 3
Survodutide
Boehringer IngelheimPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypertension16 trials
Show 13 more trials
Essential Hypertension8 trials
Show 5 more trials
Diabetic Nephropathy3 trials
High Blood Pressure2 trials
21 more indications
Atherosclerosis2 trials
CAR2 trials
Interaction1 trial
Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers
Completed·—·Phase 4·NCT01907373·12 enrolled
Efficacy and Safety1 trial
Heart Failure1 trial
Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan
Completed·—·Phase 3·NCT00417222·1,145 enrolled
Coronary Atherosclerosis1 trial
Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT)
Unknown status·—·Phase 4·NCT02360956·100 enrolled
Fasting Conditions1 trial
Cardiovascular1 trial
Overweight1 trial
Metabolic Syndrome1 trial
ART1 trial
Regulatory
FDA Approval Timeline[5]
Apr 25, 2002
BENICAR
NDA NDA021286
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Benicar drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Olmesartan medoxomil. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Type-1 Angiotensin II Receptor Antagonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- CCosette Pharmaceuticals, Inc.